Next compound en route
SPK004377 is off to our CRO for verification tests! Bon Voyage!
First Synthesized Compound
Spektron’s first compound, designed through our Q-MAP™ has been synthesized by one of our trusted CRO partners. This compound SPK003583 was designed based on bispecific targeting with de-risking models extending to the human endpoint. That’s to say that we modeled on data from Clinical Trials and used that information to create a novel molecule library …
Spektron Systems in NYC panel at BIO CEO Summit
Dr. David Wolf will be speaking on a panel presentation about AI in Healthcare and Spektron’s unique approach to medicinal molecule design. This invite-only presentation will be attended by investors looking to learn more about AI in this industry. Hosted by IMPACTIVE BioConsult, this presentation appends the 2019 BIO CEO SUMMIT and is being held 7:00 pm at Morgan Stanley.
Dr. Wolf backstage at a Beryl Elites Investor Conference
Dr. David Wolf, the President and Chief Medical Officer for Spektron Systems, sat on the panel with other distinguished speakers talking about Artificial Intelligence. In this backstage interview clip, he about the revolutionary impact that AI is having in many industries. He addresses one of the key components of any good machine learning implementation – “Curation! Curation! Curation!”
Spektron Systems meets the Natural State Angel Association
We’re excited to be presenting our business to the Natural State Angel Association tonight! Bob D’Agostino and Tim Dockins have set up shop for the day at the coworking space run by Startup Junkie in Fayetteville, Arkansas. We’re prepared and ready to show the attendees what we’re doing and why we think this is a …
Spektron Systems meets the Natural State Angel Association Read More »